Immediate Impact
3 by Nobel laureates 5 from Science/Nature 99 standout
Citing Papers
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Works of E. Schott being referenced
LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
2020
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
2019 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| E. Schott | 551 | 230 | 323 | 36 | 740 | |
| Akhil Chopra | 331 | 135 | 342 | 27 | 723 | |
| Antonio Cubillo Gracián | 298 | 119 | 423 | 30 | 659 | |
| F Silvestri | 316 | 163 | 329 | 41 | 907 | |
| Yuji Eso | 371 | 252 | 282 | 52 | 779 | |
| Sairy Hernandez | 354 | 153 | 299 | 25 | 673 | |
| Shigeru Yutani | 462 | 260 | 303 | 48 | 917 | |
| Xin Zhang | 586 | 330 | 206 | 59 | 905 | |
| Hong Wu | 458 | 194 | 405 | 57 | 876 | |
| Túlio Pfiffer | 644 | 255 | 269 | 19 | 861 | |
| Hülya Çetınkaya | 320 | 456 | 136 | 47 | 964 |
All Works
Loading papers...